anurajms/meta_analysis huggingface dataset:
MESH terms:
Washed versus unwashed red blood cells for transfusion for the prevention of morbidity and mortality in preterm infants
1. *Erythrocyte Transfusion [adverse effects, methods, mortality]; 2. *Erythrocytes; 3. *Sodium Chloride; 4. Blood Specimen Collection [*methods]; 5. Infant, Extremely Premature; 6. Infant, Very Low Birth Weight; 7. Intensive Care Units, Neonatal [statistics & numerical data]; 8. Length of Stay [statistics & numerical data]; 9. Randomized Controlled Trials as Topic; 10. Respiration, Artificial [statistics & numerical data]; 11. Time Factors;
MESH terms:
Antibody therapies for lymphoma in children
1. Antibodies, Monoclonal [*therapeutic use]; 2. Lymphoma [*drug therapy];
MESH terms:
Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy
1. *Antibiotic Prophylaxis; 2. Antineoplastic Combined Chemotherapy Protocols [adverse effects]; 3. Breast Neoplasms [drug therapy]; 4. Febrile Neutropenia [prevention & control]; 5. Fever [prevention & control]; 6. Granulocyte Colony-Stimulating Factor [*therapeutic use]; 7. Granulocyte-Macrophage Colony-Stimulating Factor [*therapeutic use]; 8. Infection Control [methods]; 9. Lung Neoplasms [drug therapy]; 10. Neoplasms [drug therapy, mortality]; 11. Randomized Controlled Trials as Topic; 12. Small Cell Lung Carcinoma [drug therapy];
MESH terms:
Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease
1. Anemia, Sickle Cell [*complications]; 2. Anticoagulants [*therapeutic use]; 3. Dalteparin [*therapeutic use]; 4. Heparin, Low-Molecular-Weight [*therapeutic use]; 5. Pain Measurement; 6. Peripheral Vascular Diseases [*drug therapy, etiology]; 7. Randomized Controlled Trials as Topic; 8. Tinzaparin;
MESH terms:
Recombinant factor VIIa concentrate versus plasma‐derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors
1. Acute Disease; 2. Blood Coagulation Factors [*therapeutic use]; 3. Factor VIII [immunology, therapeutic use]; 4. Factor VIIa [*therapeutic use]; 5. Hemophilia A [blood, *drug therapy]; 6. Hemophilia B [blood, *drug therapy]; 7. Hemorrhage [*drug therapy]; 8. Randomized Controlled Trials as Topic; 9. Recombinant Proteins [therapeutic use];
MESH terms:
Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia
1. *Central Venous Catheters; 2. Chronic Disease; 3. Hemorrhage [prevention & control]; 4. Liver Cirrhosis; 5. Platelet Count; 6. *Platelet Transfusion; 7. Randomized Controlled Trials as Topic; 8. Thrombocytopenia [blood, *therapy];
MESH terms:
Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. Antineoplastic Agents [adverse effects]; 2. Bone Marrow Diseases [chemically induced]; 3. Hematologic Diseases [chemically induced, *complications]; 4. Hemorrhage [*prevention & control]; 5. Platelet Count [*standards]; 6. *Platelet Transfusion; 7. Randomized Controlled Trials as Topic; 8. Stem Cell Transplantation [*adverse effects]; 9. Thrombocytopenia [etiology, *therapy];
MESH terms:
Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission
1. Antineoplastic Agents [*therapeutic use]; 2. Disease-Free Survival; 3. Induction Chemotherapy [methods]; 4. Interleukin-2 [*therapeutic use]; 5. Leukemia, Myeloid, Acute [*drug therapy, mortality]; 6. Maintenance Chemotherapy [*methods, mortality]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. Cause of Death; 2. Hematologic Neoplasms [*therapy]; 3. Hematopoietic Stem Cell Transplantation [*adverse effects]; 4. Hemorrhage [etiology, *prevention & control]; 5. Platelet Transfusion [*methods]; 6. Randomized Controlled Trials as Topic; 7. Stem Cell Transplantation [*adverse effects]; 8. Thrombocytopenia [chemically induced, *complications, therapy]; 9. Time Factors;
MESH terms:
Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma
1. Benzylamines; 2. Cyclams; 3. Early Termination of Clinical Trials; 4. Granulocyte Colony-Stimulating Factor [*pharmacology]; 5. Hematopoietic Stem Cell Mobilization [*methods]; 6. Hematopoietic Stem Cell Transplantation; 7. Heterocyclic Compounds [*pharmacology]; 8. Lymphoma [therapy]; 9. Lymphoma, Non-Hodgkin [mortality, *therapy]; 10. Multiple Myeloma [mortality, *therapy]; 11. Randomized Controlled Trials as Topic; 12. Time Factors; 13. Transplantation, Autologous;
MESH terms:
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders
1. Anemia, Aplastic [therapy]; 2. Anemia, Refractory [therapy]; 3. Bone Marrow Diseases [*therapy]; 4. Clinical Protocols; 5. Erythrocyte Transfusion [*methods]; 6. Leukemia, Myelomonocytic, Chronic [therapy]; 7. Myelodysplastic Syndromes [therapy]; 8. Randomized Controlled Trials as Topic;
MESH terms:
A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. Cause of Death; 2. Hematologic Diseases [*therapy]; 3. Hemorrhage [*prevention & control, *therapy]; 4. Platelet Transfusion [adverse effects, *methods, statistics & numerical data]; 5. Randomized Controlled Trials as Topic; 6. *Stem Cell Transplantation; 7. Thrombocytopenia [complications, *therapy]; 8. Time Factors;
MESH terms:
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia
1. Anthracyclines [*therapeutic use]; 2. Antibiotics, Antineoplastic [*therapeutic use]; 3. Daunorubicin [analogs & derivatives, therapeutic use]; 4. Doxorubicin [therapeutic use]; 5. Idarubicin [*therapeutic use]; 6. Induction Chemotherapy [*methods]; 7. Leukemia, Myeloid, Acute [*drug therapy]; 8. Mitoxantrone [therapeutic use]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell transplantation
1. Antithrombin III [therapeutic use]; 2. Cause of Death; 3. Cholagogues and Choleretics [*therapeutic use]; 4. Glutamine [therapeutic use]; 5. Hematopoietic Stem Cell Transplantation [*adverse effects]; 6. Heparin, Low‐Molecular‐Weight [therapeutic use]; 7. Hepatic Veno‐Occlusive Disease [mortality, *prevention & control]; 8. Plasma; 9. Polydeoxyribonucleotides [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Ursodeoxycholic Acid [*therapeutic use];
MESH terms:
Psychological therapies for sickle cell disease and pain
1. *Adaptation, Psychological; 2. Depression [psychology, therapy]; 3. Hemoglobin SC Disease [*therapy]; 4. Outcome Assessment, Health Care; 5. Pain [psychology]; 6. Pain Management [*methods]; 7. Psychotherapy [*methods]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis
1. Janus Kinase 1 [*antagonists & inhibitors]; 2. Janus Kinase 2 [*antagonists & inhibitors]; 3. Nitriles; 4. Primary Myelofibrosis [*drug therapy, mortality]; 5. Protein Kinase Inhibitors [*therapeutic use]; 6. Pyrazoles [*therapeutic use]; 7. Pyrimidines; 8. Quality of Life; 9. Randomized Controlled Trials as Topic;
MESH terms:
Sapropterin dihydrochloride for phenylketonuria
1. Biopterin [administration & dosage, adverse effects, *analogs & derivatives]; 2. Phenylalanine [*blood]; 3. Phenylketonurias [blood, *drug therapy]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Enzyme replacement and substrate reduction therapy for Gaucher disease
1. 1‐Deoxynojirimycin [adverse effects, analogs & derivatives]; 2. Enzyme Inhibitors [adverse effects]; 3. Enzyme Replacement Therapy [*methods]; 4. Gaucher Disease [blood, *drug therapy]; 5. Glucosylceramidase [therapeutic use]; 6. Hemoglobin A [metabolism]; 7. Hepatomegaly [drug therapy]; 8. Platelet Count; 9. Randomized Controlled Trials as Topic; 10. Splenomegaly [drug therapy]; 11. Substrate Specificity;
MESH terms:
Protein substitute for children and adults with phenylketonuria
1. *Food, Formulated; 2. Dietary Proteins [*administration & dosage]; 3. Phenylalanine [*blood]; 4. Phenylalanine Hydroxylase [deficiency]; 5. Phenylketonurias [diet therapy, *therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Artemisinin‐naphthoquine for treating uncomplicated Plasmodium falciparum malaria
1. Antimalarials [*therapeutic use]; 2. Artemether, Lumefantrine Drug Combination; 3. Artemisinins [*therapeutic use]; 4. Drug Combinations; 5. Ethanolamines [therapeutic use]; 6. Fluorenes [therapeutic use]; 7. Malaria, Falciparum [*drug therapy]; 8. Naphthoquinones [*therapeutic use]; 9. Quinolines [therapeutic use]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery
1. *Surgical Procedures, Operative; 2. *Tooth Extraction; 3. Aminocaproic Acid [therapeutic use]; 4. Antifibrinolytic Agents [*therapeutic use]; 5. Blood Loss, Surgical [*prevention & control]; 6. Factor VIIa [therapeutic use]; 7. Hemophilia A [*drug therapy]; 8. Hemophilia B [*drug therapy]; 9. Hemostasis, Surgical [*methods]; 10. Randomized Controlled Trials as Topic; 11. Recombinant Proteins [therapeutic use]; 12. Tranexamic Acid [therapeutic use];
MESH terms:
Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma
1. *Positron‐Emission Tomography [methods]; 2. Antineoplastic Agents [therapeutic use]; 3. Chemoradiotherapy [methods]; 4. Disease‐Free Survival; 5. Fluorodeoxyglucose F18; 6. Hodgkin Disease [*diagnostic imaging, mortality, pathology, *therapy]; 7. Radiopharmaceuticals; 8. Randomized Controlled Trials as Topic; 9. Selection Bias;
MESH terms:
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
1. Antibodies, Monoclonal, Humanized [*therapeutic use]; 2. Clinical Trials, Phase III as Topic; 3. Hemoglobinuria, Paroxysmal [*drug therapy]; 4. Multicenter Studies as Topic; 5. Randomized Controlled Trials as Topic;
MESH terms:
Deferasirox for managing iron overload in people with myelodysplastic syndrome
1. Benzoates [*therapeutic use]; 2. Chelation Therapy [*methods]; 3. Deferasirox; 4. Iron Chelating Agents [*therapeutic use]; 5. Iron Overload [*drug therapy]; 6. Myelodysplastic Syndromes [*complications]; 7. Triazoles [*therapeutic use];
MESH terms:
Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
1. Antimalarials [*therapeutic use]; 2. Malaria [drug therapy, *prevention & control]; 3. Mosquito Control; 4. Pregnancy Complications, Parasitic [drug therapy, *prevention & control]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for treating acute bleeding episodes in people with acquired hemophilia A
1. Factor VIII; 2. Hemophilia A [complications, *drug therapy]; 3. Hemorrhage [*drug therapy, etiology];
MESH terms:
Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic hematopoietic stem cell transplantation
1. Allografts; 2. Calcineurin Inhibitors; 3. Cyclosporine [therapeutic use]; 4. Graft vs Host Disease [mortality, *prevention & control]; 5. Hematopoietic Stem Cell Transplantation [*adverse effects]; 6. Immunosuppressive Agents [adverse effects, *therapeutic use]; 7. Methotrexate [adverse effects, *therapeutic use]; 8. Mycophenolic Acid [adverse effects, *analogs & derivatives, therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Recurrence; 11. Tacrolimus [therapeutic use];
MESH terms:
The role of additional radiotherapy for primary central nervous system lymphoma
1. Antimetabolites, Antineoplastic [therapeutic use]; 2. Central Nervous System Neoplasms [drug therapy, *radiotherapy]; 3. Combined Modality Therapy [methods]; 4. Cranial Irradiation [*methods]; 5. Cytarabine [therapeutic use]; 6. Early Termination of Clinical Trials; 7. Lymphoma [drug therapy, *radiotherapy]; 8. Methotrexate [therapeutic use]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Deferasirox for managing transfusional iron overload in people with sickle cell disease
1. Anemia, Sickle Cell [blood, *therapy]; 2. Benzoates [adverse effects, *therapeutic use]; 3. Chelation Therapy [adverse effects, *methods]; 4. Deferasirox; 5. Deferoxamine [adverse effects, therapeutic use]; 6. Erythrocyte Transfusion [adverse effects]; 7. Ferritins [blood]; 8. Iron Chelating Agents [adverse effects, *therapeutic use]; 9. Iron Overload [*drug therapy, etiology]; 10. Randomized Controlled Trials as Topic; 11. Triazoles [adverse effects, *therapeutic use];
MESH terms:
Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria
1. Antimalarials [*therapeutic use]; 2. Artemether, Lumefantrine Drug Combination; 3. Artemisinins [*therapeutic use]; 4. Artesunate; 5. Drug Combinations; 6. Drug Therapy, Combination [methods]; 7. Ethanolamines [therapeutic use]; 8. Fluorenes [therapeutic use]; 9. Malaria, Falciparum [*drug therapy]; 10. Mefloquine [therapeutic use]; 11. Parasitemia [drug therapy]; 12. Quinolines [*therapeutic use]; 13. Randomized Controlled Trials as Topic;
MESH terms:
Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine
1. Antimalarials [*administration & dosage]; 2. Chloroquine [administration & dosage]; 3. Drug Administration Schedule; 4. Malaria, Vivax [*prevention & control]; 5. Plasmodium vivax; 6. Primaquine [*administration & dosage]; 7. Randomized Controlled Trials as Topic; 8. Secondary Prevention;
MESH terms:
Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria
1. Antimalarials [*therapeutic use]; 2. Artemether, Lumefantrine Drug Combination; 3. Artemisinins [*therapeutic use]; 4. Drug Combinations; 5. Drug Resistance; 6. Drug Therapy, Combination [methods]; 7. Ethanolamines [therapeutic use]; 8. Fluorenes [therapeutic use]; 9. Malaria, Vivax [*drug therapy, prevention & control]; 10. Parasitemia [*drug therapy]; 11. Primaquine [therapeutic use]; 12. Pyrimethamine [therapeutic use]; 13. Quinolines [therapeutic use]; 14. Randomized Controlled Trials as Topic; 15. Secondary Prevention; 16. Sulfadoxine [therapeutic use];
MESH terms:
Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment
1. Immunotherapy; 2. Mouth; 3. Neck; 4. *Neoplasm Recurrence, Local; 5. *Oropharyngeal Neoplasms [surgery]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Hyperbaric oxygen therapy for late radiation tissue injury
1. *Barotrauma [therapy]; 2. Disease Progression; 3. *Hyperbaric Oxygenation [methods]; 4. *Neoplasms [therapy]; 5. *Osteoradionecrosis [prevention & control]; 6. Pain; 7. *Radiation Injuries [prevention & control];
MESH terms:
Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
1. Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; 2. Carboplatin [therapeutic use]; 3. *Carcinoma, Non-Small-Cell Lung [drug therapy, genetics]; 4. Cisplatin; 5. *Lung Neoplasms [drug therapy, genetics]; 6. Mutation;
MESH terms:
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
1. *Antineoplastic Agents [adverse effects]; 2. Carcinoma, Ovarian Epithelial [drug therapy]; 3. *Ovarian Neoplasms [drug therapy]; 4. Randomized Controlled Trials as Topic; 5. Recurrence; 6. Systematic Reviews as Topic;
MESH terms:
Local versus radical surgery for early rectal cancer with or without neoadjuvant or adjuvant therapy
1. Abdominal Pain; 2. Combined Modality Therapy; 3. *Neoadjuvant Therapy; 4. Neoplasm Recurrence, Local [epidemiology]; 5. *Rectal Neoplasms [surgery];
MESH terms:
Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications and improve quality of life in colorectal cancer surgery
1. *Colorectal Neoplasms [surgery]; 2. *Digestive System Surgical Procedures; 3. Postoperative Complications [prevention & control]; 4. Preoperative Exercise; 5. Quality of Life;
MESH terms:
First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis
1. Axitinib; 2. *Carcinoma, Renal Cell [drug therapy]; 3. Network Meta-Analysis; 4. Nivolumab; 5. Sunitinib;
MESH terms:
Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
1. *Angiogenesis Inhibitors [adverse effects]; 2. Bevacizumab [adverse effects]; 3. Carcinoma, Ovarian Epithelial [drug therapy]; 4. Neoplasm Recurrence, Local [chemically induced, drug therapy]; 5. *Ovarian Neoplasms [drug therapy]; 6. Vascular Endothelial Growth Factor A;
MESH terms:
Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk
1. *Breast Neoplasms [diagnostic imaging]; 2. Early Detection of Cancer; 3. Mammography; 4. Randomized Controlled Trials as Topic; 5. *Ultrasonography, Mammary;
MESH terms:
Interventions for weight reduction in obesity to improve survival in women with endometrial cancer
1. *COVID-19 [complications]; 2. *Endometrial Neoplasms [therapy]; 3. Obesity [complications, therapy]; 4. Overweight [complications, therapy]; 5. Weight Loss;
MESH terms:
Skin‐sparing mastectomy for the treatment of breast cancer
1. *Breast Neoplasms [surgery]; 2. *Carcinoma, Intraductal, Noninfiltrating [etiology, surgery]; 3. *Mammaplasty [adverse effects]; 4. Mastectomy [adverse effects, methods]; 5. Necrosis;
MESH terms:
Exercise interventions for adults with cancer receiving radiation therapy alone
1. *Exercise; 2. Exercise Therapy [adverse effects]; 3. Fatigue [etiology, therapy]; 4. *Neoplasms [complications, radiotherapy]; 5. Quality of Life; 6. Walk Test; 7. Walking;
MESH terms:
Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer
1. Prostatectomy [adverse effects]; 2. *Prostatic Neoplasms [pathology]; 3. Systematic Reviews as Topic;
MESH terms:
Preoperative combined mechanical and oral antibiotic bowel preparation for preventing complications in elective colorectal surgery
1. Anastomotic Leak [drug therapy, prevention & control]; 2. *Anti-Bacterial Agents [administration & dosage, therapeutic use]; 3. *Colorectal Surgery [adverse effects]; 4. *Ileus [drug therapy, prevention & control]; 5. Preoperative Care; 6. *Surgical Wound Infection [drug therapy, prevention & control];
MESH terms:
Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer
1. Adrenal Cortex Hormones [adverse effects]; 2. Dexamethasone [adverse effects]; 3. Fatigue [drug therapy, etiology]; 4. Modafinil; 5. *Neoplasms [complications, drug therapy]; 6. *Quality of Life;
MESH terms:
Neoadjuvant treatment for stage III and IV cutaneous melanoma
1. *Antineoplastic Agents [adverse effects]; 2. Ipilimumab; 3. *Melanoma [drug therapy, pathology]; 4. Melanoma, Cutaneous Malignant; 5. Neoplasm Staging; 6. Nivolumab; 7. Randomized Controlled Trials as Topic; 8. *Skin Neoplasms [drug therapy, pathology];
MESH terms:
Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer
1. *Agaricales; 2. *Colorectal Neoplasms [drug therapy, radiotherapy]; 3. *Drug-Related Side Effects and Adverse Reactions; 4. Nausea; 5. *Neutropenia; 6. Randomized Controlled Trials as Topic; 7. Trametes;
MESH terms:
Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer
1. *Antifungal Agents [adverse effects]; 2. *Febrile Neutropenia [chemically induced, prevention & control]; 3. Invasive Fungal Infections [drug therapy, prevention & control]; 4. *Neoplasms [drug therapy]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation
1. *Brain Neoplasms; 2. Cognition; 3. *Cognitive Dysfunction [etiology, prevention & control]; 4. Cranial Irradiation [adverse effects]; 5. *Dementia; 6. Donepezil; 7. Fatigue [etiology, prevention & control]; 8. Memantine; 9. *Methylphenidate [therapeutic use]; 10. Modafinil [therapeutic use]; 11. Quality of Life;
MESH terms:
Preoperative exercise training for people with non‐small cell lung cancer
1. *Carcinoma, Non-Small-Cell Lung [surgery]; 2. Dyspnea; 3. Fatigue; 4. Forced Expiratory Volume; 5. *Lung Neoplasms [surgery]; 6. Postoperative Complications [epidemiology];
MESH terms:
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines
1. Anthracyclines [adverse effects]; 2. Antibiotics, Antineoplastic [adverse effects]; 3. Cardiotonic Agents [therapeutic use]; 4. Cardiotoxicity [drug therapy, etiology, prevention & control]; 5. *Dexrazoxane [therapeutic use]; 6. *Heart Failure [drug therapy]; 7. *Leukemia, Myeloid, Acute [drug therapy]; 8. *Polyketides [therapeutic use]; 9. Systematic Reviews as Topic;
MESH terms:
Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3/II cervical cancer
1. Chemoradiotherapy [methods]; 2. Cytoreduction Surgical Procedures; 3. Hysterectomy [methods]; 4. Neoplasm Staging; 5. Neoplasm, Residual; 6. *Uterine Cervical Neoplasms [pathology, therapy];
MESH terms:
Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care
1. Analgesics, Opioid [adverse effects]; 2. Naloxone; 3. Naltrexone [analogs & derivatives]; 4. Narcotic Antagonists [adverse effects]; 5. *Neoplasms [drug therapy]; 6. *Opioid-Induced Constipation; 7. Oxycodone; 8. Palliative Care; 9. Quaternary Ammonium Compounds; 10. *Substance Withdrawal Syndrome;
MESH terms:
Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer
1. *Carcinoma, Ovarian Epithelial [pathology, surgery]; 2. Controlled Clinical Trials as Topic; 3. *Cytoreduction Surgical Procedures; 4. Disease Progression; 5. Observational Studies as Topic; 6. *Ovarian Neoplasms [pathology, surgery]; 7. Treatment Outcome;
MESH terms:
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer
1. Chemoradiotherapy [adverse effects, methods]; 2. Chemotherapy, Adjuvant [methods]; 3. Hysterectomy; 4. Neoadjuvant Therapy [methods]; 5. *Uterine Cervical Neoplasms [drug therapy, radiotherapy];
MESH terms:
Impact of low‐dose computed tomography (LDCT) screening on lung cancer‐related mortality
1. Bias; 2. *Early Detection of Cancer [methods]; 3. *Lung Neoplasms [diagnostic imaging, mortality]; 4. Randomized Controlled Trials as Topic; 5. Tomography, X-Ray Computed [methods];
MESH terms:
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer
1. Alopecia [drug therapy]; 2. Bridged-Ring Compounds; 3. Carcinoma, Ovarian Epithelial [drug therapy]; 4. Neoplasm Recurrence, Local [drug therapy]; 5. *Neutropenia; 6. *Ovarian Neoplasms [drug therapy]; 7. Paclitaxel [adverse effects]; 8. Taxoids [adverse effects];
MESH terms:
Oxycodone for cancer‐related pain
1. Analgesics, Opioid [adverse effects]; 2. *Cancer Pain [drug therapy]; 3. Constipation [chemically induced]; 4. Morphine [adverse effects]; 5. Nausea [chemically induced, drug therapy]; 6. *Neoplasms [complications, drug therapy]; 7. Oxycodone [adverse effects]; 8. Pain [drug therapy, etiology]; 9. Quality of Life; 10. Reproducibility of Results; 11. Sleepiness; 12. Vomiting [chemically induced];
MESH terms:
Perioperative enhanced recovery programmes for women with gynaecological cancers
1. Length of Stay; 2. *Neoplasms; 3. Perioperative Care; 4. Postoperative Complications [epidemiology, prevention & control]; 5. Quality of Life;
MESH terms:
Gases for establishing pneumoperitoneum during laparoscopic abdominal surgery
1. Carbon Dioxide [adverse effects]; 2. Helium [adverse effects]; 3. *Insufflation [adverse effects, methods]; 4. *Laparoscopy [adverse effects, methods]; 5. Nitrous Oxide [adverse effects]; 6. *Pneumoperitoneum [etiology];
MESH terms:
Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer
1. Bevacizumab [therapeutic use]; 2. Carboplatin [adverse effects]; 3. Carcinoma, Ovarian Epithelial [drug therapy, surgery]; 4. *Ovarian Neoplasms [surgery]; 5. *Paclitaxel [adverse effects];
MESH terms:
Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
1. Carcinoma, Ovarian Epithelial [drug therapy, surgery]; 2. Neoplasm Recurrence, Local [drug therapy]; 3. *Ovarian Neoplasms [drug therapy, genetics]; 4. *Poly(ADP-ribose) Polymerase Inhibitors [adverse effects]; 5. Poly(ADP-ribose) Polymerases [therapeutic use];
MESH terms:
Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy
1. Length of Stay; 2. *Pancreatectomy; 3. Pancreatic Fistula; 4. *Pancreaticoduodenectomy [adverse effects]; 5. Postoperative Complications;
MESH terms:
Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
1. Aromatase Inhibitors [adverse effects]; 2. *Breast Neoplasms [drug therapy]; 3. *Musculoskeletal Pain [chemically induced, drug therapy, prevention & control]; 4. Quality of Life; 5. Tamoxifen [adverse effects];
MESH terms:
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
1. Anaplastic Lymphoma Kinase [genetics]; 2. *Carcinoma, Non-Small-Cell Lung [drug therapy, genetics]; 3. *Lung Neoplasms [drug therapy, genetics]; 4. Progression-Free Survival; 5. Protein Kinase Inhibitors [adverse effects];
MESH terms:
Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers
1. *Brain Neoplasms [therapy]; 2. *Caregivers; 3. Exercise; 4. Palliative Care; 5. Quality of Life;
MESH terms:
Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
1. Chemoradiotherapy, Adjuvant; 2. *Mouth Neoplasms [drug therapy]; 3. Neoplasm Recurrence, Local; 4. *Oropharyngeal Neoplasms [drug therapy];
MESH terms:
Prophylactic abdominal drainage for pancreatic surgery
1. *Abdomen [surgery]; 2. *Drainage; 3. Length of Stay; 4. Pancreas; 5. Pancreatic Fistula;
MESH terms:
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent
1. *Carcinoma, Non-Small-Cell Lung [drug therapy]; 2. Chemoradiotherapy; 3. Immunotherapy; 4. *Lung Neoplasms [drug therapy]; 5. Progression-Free Survival; 6. Randomized Controlled Trials as Topic;
MESH terms:
Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer
1. *Carcinoma, Transitional Cell [surgery]; 2. Cystectomy [adverse effects]; 3. Neoplasm Recurrence, Local; 4. *Urinary Bladder Neoplasms [surgery];
MESH terms:
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis
1. *Antiemetics [therapeutic use]; 2. *Antineoplastic Agents [adverse effects]; 3. Nausea [chemically induced, drug therapy, prevention & control]; 4. Network Meta-Analysis; 5. Palonosetron [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Vomiting [chemically induced, drug therapy, prevention & control];
MESH terms:
Perioperative systemic nonsteroidal anti‐inflammatory drugs (NSAIDs) in women undergoing breast surgery
1. Anti-Inflammatory Agents, Non-Steroidal [adverse effects]; 2. *Breast Neoplasms [surgery]; 3. Ketorolac [therapeutic use]; 4. Pain, Postoperative [drug therapy]; 5. *Pharmaceutical Preparations;
MESH terms:
Music interventions for improving psychological and physical outcomes in people with cancer
1. Anxiety; 2. *Music; 3. *Music Therapy; 4. *Neoplasms [therapy]; 5. Quality of Life;
MESH terms:
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation
1. Anticoagulants [adverse effects]; 2. Heparin; 3. Heparin, Low-Molecular-Weight; 4. *Neoplasms [complications, drug therapy]; 5. Systematic Reviews as Topic; 6. *Venous Thromboembolism [prevention & control];
MESH terms:
Prophylactic antibiotics for preventing gram‐positive infections associated with long‐term central venous catheters in adults and children receiving treatment for cancer
1. Anti-Bacterial Agents [therapeutic use]; 2. *Catheter-Related Infections [prevention & control]; 3. *Central Venous Catheters [adverse effects]; 4. Heparin; 5. *Neoplasms [complications, drug therapy];
MESH terms:
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
1. Anticoagulants [adverse effects]; 2. *Fibrinolytic Agents; 3. Heparin; 4. Heparin, Low-Molecular-Weight; 5. *Multiple Myeloma [drug therapy];
MESH terms:
School‐based physical activity programs for promoting physical activity and fitness in children and adolescents aged 6 to 18
1. *Exercise; 2. Physical Fitness; 3. *Quality of Life; 4. Randomized Controlled Trials as Topic; 5. Schools; 6. Sedentary Behavior;
MESH terms:
Roux‐en‐Y versus Billroth‐I reconstruction after distal gastrectomy for gastric cancer
1. Anastomosis, Roux-en-Y [adverse effects]; 2. Gastrectomy [adverse effects]; 3. Postoperative Complications; 4. Randomized Controlled Trials as Topic; 5. *Stomach Neoplasms [surgery];
MESH terms:
Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma
1. *Bile Duct Neoplasms [drug therapy, surgery]; 2. Bile Ducts, Intrahepatic; 3. Chemotherapy, Adjuvant; 4. *Cholangiocarcinoma [drug therapy, surgery]; 5. Neoplasm Recurrence, Local; 6. Quality of Life;
MESH terms:
Interventions targeted at women to encourage the uptake of cervical screening
1. Bias; 2. Mass Screening; 3. *Uterine Cervical Neoplasms [diagnosis, prevention & control]; 4. Vaccination;
MESH terms:
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma
1. Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; 2. *Hematopoietic Stem Cell Transplantation; 3. Progression-Free Survival; 4. *Sarcoma, Ewing [drug therapy]; 5. Transplantation, Autologous;
MESH terms:
Partial breast irradiation versus whole breast radiotherapy for early breast cancer
1. *Breast Neoplasms [radiotherapy, surgery]; 2. *Carcinoma, Intraductal, Noninfiltrating; 3. Mastectomy; 4. Mastectomy, Segmental; 5. Radiation Dose Hypofractionation;
MESH terms:
Hydromorphone for cancer pain
1. Analgesics, Opioid [adverse effects]; 2. *Cancer Pain [drug therapy]; 3. Hydromorphone [adverse effects]; 4. Morphine [adverse effects]; 5. *Neoplasms [complications]; 6. Oxycodone;
MESH terms:
Degarelix for treating advanced hormone‐sensitive prostate cancer
1. Disease Progression; 2. Hormones; 3. Oligopeptides; 4. *Prostatic Neoplasms [drug therapy]; 5. *Quality of Life;
MESH terms:
Physical therapy interventions, other than general physical exercise interventions, in children and adolescents before, during and following treatment for cancer
1. *Exercise; 2. Exercise Therapy; 3. *Neoplasms [therapy]; 4. Physical Fitness; 5. Physical Therapy Modalities; 6. Quality of Life;
MESH terms:
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer
1. Antineoplastic Agents [*therapeutic use]; 2. Bias; 3. *Carcinoma, Ovarian Epithelial [drug therapy, mortality, pathology, surgery]; 4. Chemotherapy, Adjuvant [methods, mortality]; 5. Cytoreduction Surgical Procedures [adverse effects, *methods, mortality]; 6. Neoadjuvant Therapy [*methods]; 7. *Ovarian Neoplasms [drug therapy, mortality, pathology, surgery]; 8. Postoperative Complications [epidemiology, etiology]; 9. Preoperative Care; 10. Progression-Free Survival; 11. Randomized Controlled Trials as Topic; 12. Treatment Outcome;
MESH terms:
Protons versus photons for the treatment of chordoma
1. Bias; 2. Bone Neoplasms [mortality, *radiotherapy]; 3. Chordoma [mortality, *radiotherapy]; 4. Disease-Free Survival; 5. Neoplasm Recurrence, Local [prevention & control]; 6. Observational Studies as Topic; 7. Photons [adverse effects, *therapeutic use]; 8. Progression-Free Survival; 9. Proton Therapy [adverse effects, *methods]; 10. Radiosurgery [methods]; 11. Radiotherapy, Adjuvant; 12. Radiotherapy, Intensity-Modulated [methods]; 13. Time Factors;
MESH terms:
Intravesical gemcitabine for non‐muscle invasive bladder cancer
1. Adjuvants, Immunologic [administration & dosage]; 2. Administration, Intravesical; 3. Antibiotics, Antineoplastic [administration & dosage, adverse effects]; 4. Antimetabolites, Antineoplastic [*administration & dosage, adverse effects]; 5. BCG Vaccine [administration & dosage]; 6. Bias; 7. Cause of Death; 8. Confidence Intervals; 9. Deoxycytidine [administration & dosage, adverse effects, *analogs & derivatives]; 10. Disease Progression; 11. Drug Administration Schedule; 12. Gemcitabine; 13. Mitomycin [administration & dosage, adverse effects]; 14. Neoplasm Recurrence, Local [*drug therapy, mortality, prevention & control]; 15. Randomized Controlled Trials as Topic; 16. Saline Solution [administration & dosage]; 17. Urinary Bladder Neoplasms [*drug therapy, mortality, pathology, prevention & control];
MESH terms:
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
1. Antibodies, Monoclonal [therapeutic use]; 2. Antibodies, Monoclonal, Humanized [therapeutic use]; 3. Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; 4. B7-H1 Antigen [metabolism]; 5. Bevacizumab [adverse effects, *therapeutic use]; 6. Bias; 7. Carcinoma, Non-Small-Cell Lung [*drug therapy, metabolism, mortality, pathology]; 8. Immune Checkpoint Inhibitors [adverse effects, *therapeutic use]; 9. Lung Neoplasms [*drug therapy, mortality, pathology]; 10. Nivolumab [adverse effects, therapeutic use]; 11. Platinum Compounds [adverse effects, therapeutic use]; 12. Progression-Free Survival; 13. Randomized Controlled Trials as Topic;
MESH terms:
PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer
1. Bias; 2. Breast Neoplasms [chemistry, *drug therapy, genetics, pathology]; 3. Genes, BRCA1; 4. Genes, BRCA2; 5. Germ-Line Mutation; 6. Poly(ADP-ribose) Polymerase Inhibitors [adverse effects, *therapeutic use]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Triple Negative Breast Neoplasms [drug therapy, genetics, pathology];
MESH terms:
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
1. Afatinib [adverse effects, therapeutic use]; 2. Antineoplastic Agents [adverse effects, *therapeutic use]; 3. Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; 4. Bias; 5. Carboplatin [therapeutic use]; 6. Carcinoma, Non-Small-Cell Lung [*drug therapy, genetics, mortality]; 7. Cetuximab [adverse effects, therapeutic use]; 8. Crown Ethers [adverse effects, therapeutic use]; 9. ErbB Receptors [*genetics]; 10. Erlotinib Hydrochloride [adverse effects, therapeutic use]; 11. Gefitinib [adverse effects, therapeutic use]; 12. Lung Neoplasms [*drug therapy, genetics, mortality]; 13. *Mutation; 14. Paclitaxel [therapeutic use]; 15. Pemetrexed [therapeutic use]; 16. Progression-Free Survival; 17. Protein Kinase Inhibitors [adverse effects, therapeutic use]; 18. Quality of Life; 19. Quinazolines [adverse effects, therapeutic use]; 20. Randomized Controlled Trials as Topic;
MESH terms:
Exercise for cancer cachexia in adults
1. Bias; 2. Cachexia [etiology, *therapy]; 3. Combined Modality Therapy [methods]; 4. *Exercise; 5. Exercise Tolerance; 6. Fatigue [etiology]; 7. Head and Neck Neoplasms [complications]; 8. Lung Neoplasms [complications]; 9. Muscle Strength; 10. Neoplasms [*complications]; 11. Pancreatic Neoplasms [complications]; 12. Patient Compliance; 13. Physical Endurance; 14. Quality of Life; 15. Randomized Controlled Trials as Topic; 16. Thinness;
MESH terms:
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer
1. Angiogenesis Inhibitors [adverse effects, *therapeutic use]; 2. Antineoplastic Agents [adverse effects, *therapeutic use]; 3. Bevacizumab [adverse effects, therapeutic use]; 4. Bias; 5. Brachytherapy [adverse effects]; 6. Combined Modality Therapy [adverse effects, methods]; 7. Confidence Intervals; 8. Gastric Fistula [chemically induced]; 9. Gastrointestinal Hemorrhage [chemically induced]; 10. Hypertension [chemically induced]; 11. Indazoles; 12. Intestinal Fistula [chemically induced]; 13. Intestinal Perforation [chemically induced]; 14. Lapatinib [adverse effects, therapeutic use]; 15. Neoplasm Recurrence, Local [blood supply, *drug therapy, mortality]; 16. Progression-Free Survival; 17. Pyridines [adverse effects, therapeutic use]; 18. Pyrimidines [adverse effects, therapeutic use]; 19. Quality of Life; 20. Quinazolines [adverse effects, therapeutic use]; 21. Randomized Controlled Trials as Topic; 22. Sulfonamides [adverse effects, therapeutic use]; 23. Thromboembolism [chemically induced]; 24. Uterine Cervical Neoplasms [blood supply, *drug therapy, mortality]; 25. Vascular Endothelial Growth Factor A [*antagonists & inhibitors];
MESH terms:
Paravertebral anaesthesia with or without sedation versus general anaesthesia for women undergoing breast cancer surgery
1. Analgesia [*methods]; 2. Anesthesia Recovery Period; 3. Anesthesia, General [*methods]; 4. Anesthesia, Spinal [adverse effects, *methods]; 5. Bias; 6. Breast Neoplasms [immunology, *surgery]; 7. Early Ambulation; 8. Horner Syndrome [epidemiology]; 9. Incidence; 10. Intention to Treat Analysis; 11. Length of Stay; 12. Nerve Block [methods]; 13. Pain Measurement [methods]; 14. Pain, Postoperative [diagnosis, prevention & control]; 15. Patient Satisfaction; 16. Postoperative Nausea and Vomiting [epidemiology, prevention & control]; 17. Randomized Controlled Trials as Topic; 18. Stress, Physiological [*drug effects];
MESH terms:
Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis
1. *Brain Neoplasms; 2. *Glioblastoma [therapy]; 3. Lomustine [therapeutic use]; 4. Neoplasm Recurrence, Local [drug therapy]; 5. Network Meta-Analysis;
MESH terms:
Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen
1. Adenocarcinoma [chemically induced, prevention & control]; 2. Antineoplastic Agents, Hormonal [adverse effects]; 3. Breast Neoplasms [chemistry, mortality, *prevention & control]; 4. Chemotherapy, Adjuvant; 5. Confidence Intervals; 6. Contraceptive Agents, Female [administration & dosage]; 7. Endometrial Hyperplasia [chemically induced, epidemiology, *prevention & control]; 8. Endometrial Neoplasms [chemically induced, epidemiology, *prevention & control]; 9. *Intrauterine Devices, Medicated; 10. Levonorgestrel [*administration & dosage, adverse effects]; 11. Neoplasm Recurrence, Local [mortality, *prevention & control]; 12. Polyps [chemically induced, epidemiology, prevention & control]; 13. Randomized Controlled Trials as Topic; 14. Tamoxifen [adverse effects]; 15. Uterine Hemorrhage [chemically induced, epidemiology]; 16. Uterus [drug effects];
MESH terms:
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer
1. Abiraterone Acetate [adverse effects, *therapeutic use]; 2. Androgen Antagonists [adverse effects, *therapeutic use]; 3. Antineoplastic Agents, Hormonal [*therapeutic use]; 4. Disease Progression; 5. Neoplasm Grading; 6. Prostatic Neoplasms [*drug therapy, mortality, pathology]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Withholding Treatment [statistics & numerical data];
MESH terms:
Body weight management in overweight and obese breast cancer survivors
1. Body Mass Index; 2. Breast Neoplasms [*complications, epidemiology]; 3. *Cancer Survivors; 4. Combined Modality Therapy [methods]; 5. Exercise; 6. Neoplasm Recurrence, Local [epidemiology]; 7. Obesity [*therapy]; 8. Overweight [*therapy]; 9. Psychotherapy; 10. Quality of Life; 11. Randomized Controlled Trials as Topic; 12. Waist Circumference; 13. *Weight Loss; 14. Weight Reduction Programs;
MESH terms:
Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis
1. Alendronate [adverse effects, therapeutic use]; 2. Antineoplastic Agents, Hormonal [therapeutic use]; 3. Bisphosphonate-Associated Osteonecrosis of the Jaw [etiology]; 4. Bone Density Conservation Agents [adverse effects, *therapeutic use]; 5. Bone Neoplasms [*drug therapy, *secondary]; 6. Clodronic Acid [adverse effects, therapeutic use]; 7. Denosumab [adverse effects, *therapeutic use]; 8. Diphosphonates [adverse effects, *therapeutic use]; 9. Etidronic Acid [adverse effects, therapeutic use]; 10. Network Meta-Analysis; 11. Pamidronate [adverse effects, therapeutic use]; 12. Prostatic Neoplasms [drug therapy, *pathology]; 13. Prostatic Neoplasms, Castration-Resistant [pathology]; 14. Quality of Life; 15. Randomized Controlled Trials as Topic; 16. RANK Ligand [*antagonists & inhibitors]; 17. Risedronic Acid [adverse effects, therapeutic use]; 18. Zoledronic Acid [adverse effects, therapeutic use];
MESH terms:
Platinum‐containing regimens for triple‐negative metastatic breast cancer
1. Antineoplastic Agents [adverse effects, *therapeutic use]; 2. Bias; 3. Carboplatin [adverse effects, *therapeutic use]; 4. Cisplatin [adverse effects, *therapeutic use]; 5. Genes, BRCA1; 6. Genes, BRCA2; 7. Nausea [chemically induced]; 8. Oxaliplatin [adverse effects, *therapeutic use]; 9. Progression-Free Survival; 10. Randomized Controlled Trials as Topic; 11. Triple Negative Breast Neoplasms [*drug therapy, genetics, mortality]; 12. Vomiting [chemically induced];
MESH terms:
Targeted therapy for metastatic renal cell carcinoma
1. Antibodies, Monoclonal, Humanized [adverse effects, therapeutic use]; 2. Antineoplastic Agents [adverse effects, *therapeutic use]; 3. Antineoplastic Agents, Immunological [therapeutic use]; 4. Axitinib [adverse effects, therapeutic use]; 5. Bevacizumab [adverse effects, therapeutic use]; 6. Bias; 7. Carcinoma, Renal Cell [*drug therapy, mortality]; 8. Everolimus [adverse effects, therapeutic use]; 9. Indazoles; 10. Ipilimumab [adverse effects, therapeutic use]; 11. Kidney Neoplasms [*drug therapy, mortality, pathology]; 12. Phenylurea Compounds [adverse effects, therapeutic use]; 13. Progression-Free Survival; 14. Protein Kinase Inhibitors [adverse effects, *therapeutic use]; 15. Pyrimidines [adverse effects, therapeutic use]; 16. Quality of Life; 17. Quinolines [adverse effects, therapeutic use]; 18. Randomized Controlled Trials as Topic; 19. Receptors, Vascular Endothelial Growth Factor [antagonists & inhibitors]; 20. Sirolimus [adverse effects, analogs & derivatives, therapeutic use]; 21. Sorafenib [adverse effects, therapeutic use]; 22. Sulfonamides [adverse effects, therapeutic use]; 23. Sunitinib [adverse effects, therapeutic use];
MESH terms:
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
1. Anticoagulants [adverse effects, *therapeutic use]; 2. Antineoplastic Agents [*adverse effects]; 3. Antithrombins [adverse effects, therapeutic use]; 4. Asparaginase [*adverse effects]; 5. Bias; 6. Cause of Death; 7. Placebos [therapeutic use]; 8. Precursor Cell Lymphoblastic Leukemia-Lymphoma [*drug therapy]; 9. Venous Thromboembolism [chemically induced, mortality, *prevention & control];
MESH terms:
The effectiveness and cost‐effectiveness of hospital‐based specialist palliative care for adults with advanced illness and their caregivers
1. Ambulatory Care [economics]; 2. Bias; 3. Caregivers [psychology, *statistics & numerical data]; 4. Cost-Benefit Analysis; 5. Family; 6. Heart Failure [mortality, therapy]; 7. Home Care Services, Hospital-Based [*economics]; 8. Hospitalization [economics]; 9. Neoplasms [mortality, therapy]; 10. Pain Management [statistics & numerical data]; 11. Palliative Care [*economics, *methods]; 12. Patient Satisfaction; 13. Quality of Life; 14. Randomized Controlled Trials as Topic; 15. Symptom Assessment [statistics & numerical data]; 16. Terminal Care [*economics, *methods];
MESH terms:
Retzius‐sparing versus standard robotic‐assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
1. Kallikreins [blood]; 2. Laparoscopy [adverse effects, methods]; 3. Margins of Excision; 4. Organ Sparing Treatments [adverse effects, *methods]; 5. Penile Erection; 6. Postoperative Complications [epidemiology, *prevention & control]; 7. Prostate-Specific Antigen [blood]; 8. Prostatectomy [adverse effects, *methods]; 9. Prostatic Neoplasms [blood, pathology, *surgery]; 10. Randomized Controlled Trials as Topic; 11. Robotic Surgical Procedures [adverse effects, *methods]; 12. Time Factors; 13. Treatment Outcome; 14. Urinary Incontinence [epidemiology, *prevention & control];
MESH terms:
Helicobacter pylori eradication for the prevention of gastric neoplasia
1. Anti-Bacterial Agents [*therapeutic use]; 2. Anti-Ulcer Agents [therapeutic use]; 3. Asymptomatic Infections [*therapy]; 4. Carcinoma, Squamous Cell [epidemiology]; 5. Drug Therapy, Combination [adverse effects, methods]; 6. Esophageal Neoplasms [epidemiology]; 7. Helicobacter Infections [*drug therapy]; 8. *Helicobacter pylori; 9. Incidence; 10. Precancerous Conditions [drug therapy]; 11. Randomized Controlled Trials as Topic; 12. Stomach Neoplasms [microbiology, mortality, *prevention & control];
MESH terms:
Radical prostatectomy versus deferred treatment for localised prostate cancer
1. Cause of Death; 2. Disease Progression; 3. Erectile Dysfunction [epidemiology]; 4. Palliative Care; 5. Postoperative Complications [epidemiology]; 6. Prostatectomy [adverse effects, *methods, mortality]; 7. Prostatic Neoplasms [mortality, pathology, surgery, *therapy]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Urinary Incontinence [epidemiology]; 11. *Watchful Waiting;
MESH terms:
Telephone interventions for symptom management in adults with cancer
1. Anxiety [etiology, therapy]; 2. Cancer Pain [therapy]; 3. Depression [etiology, therapy]; 4. Dyspnea [etiology, therapy]; 5. Fatigue [etiology, therapy]; 6. Neoplasms [*complications, psychology, therapy]; 7. Randomized Controlled Trials as Topic; 8. Self Care; 9. Sexual Dysfunction, Physiological [etiology, therapy]; 10. Stress, Psychological [etiology, therapy]; 11. Symptom Assessment; 12. Telemedicine [*methods]; 13. *Telephone [statistics & numerical data]; 14. Time Factors; 15. Uncertainty;
MESH terms:
Surgery versus radical endotherapies for early cancer and high‐grade dysplasia in Barrett's oesophagus
1. Barrett Esophagus [pathology, *surgery]; 2. Esophageal Neoplasms [pathology, *surgery]; 3. Esophagoscopy [*methods]; 4. Precancerous Conditions [pathology, *surgery];
MESH terms:
External beam radiation dose escalation for high grade glioma
1. Age Factors; 2. Brain Neoplasms [mortality, pathology, *radiotherapy]; 3. Cranial Irradiation [*methods, mortality]; 4. Disease-Free Survival; 5. *Dose Fractionation, Radiation; 6. Glioma [mortality, pathology, *radiotherapy]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Survival Analysis;
MESH terms:
Physical activity interventions for disease‐related physical and mental health during and following treatment in people with non‐advanced colorectal cancer
1. Anxiety [etiology]; 2. Colonic Neoplasms [complications, psychology, therapy]; 3. Colorectal Neoplasms [*complications, psychology, therapy]; 4. Depression [etiology, therapy]; 5. *Exercise; 6. Fatigue [therapy]; 7. *Mental Health; 8. *Physical Fitness; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Time Factors;